Biotechnology in 2026: Innovation amid industry transformation

As 2026 begins, the biotechnology sector is regaining momentum as policy and reimbursement headwinds ease and attention shifts back to fundamentals. A more stable backdrop around tariffs, pricing frameworks and trade policy is giving investors clearer visibility on long-term growth drivers. At the same time, rapid scientific progress across new modalities and unmet medical needs continues to support the sector’s structural growth story.

Yet this recovery is uneven, with capital discipline and structural pressures widening performance gaps between companies. In our view, this environment favors a selective, active approach that emphasizes strong balance sheets, credible development paths and clear routes to commercialization in order to convert innovation into durable value.